2,2-二甲基四氢吡喃-4-甲醛 | 34941-21-4

• 物质功能分类: 医药中间体 - 吡喃类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 中文名称: 2,2-二甲基四氢吡喃-4-甲醛
• 中文别名: 2,2-二甲基-四氢吡喃基-4-甲醛；2,2-二甲基-四氢-2H-吡喃-4-甲醛
• 英文名称: 2,2-dimethyltetrahydro-2H-pyran-4-carbaldehyde
• 英文别名: 2,2-dimethyltetrahydropyran-4-carbaldehyde；2,2-dimethyloxane-4-carbaldehyde
• CAS: 34941-21-4
• 化学式: C₈H₁₄O₂
• 分子量: 142.198
• InChiKey: LQCOXFCJGIILHS-UHFFFAOYSA-N

物化性质

• 沸点：
  61 °C(Press: 7 Torr)
• 密度：
  0.9910 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2932999099

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2,2-Dimethyl-tetrahydro-pyran-4-carbaldehyde
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2,2-Dimethyl-tetrahydro-pyran-4-carbaldehyde
CAS number: 34941-21-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H14O2
Molecular weight: 142.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,2-二甲基四氢吡喃-4-甲醛 在 四氢吡咯 、 titanium(IV) tetraethanolate 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 73.5h， 生成 6-Bromo-2-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-4'-methylspiro[chroman-4,2'-imidazole]-5'(1'H)-thione
  参考文献：
  名称：

  Compounds and their use as BACE Inhibitors

  摘要：

  本发明涉及式(I)的化合物及其药物组合物。此外，本发明涉及治疗方法，用于治疗和/或预防与Aβ相关的病理，如唐氏综合症，β-淀粉样蛋白血管病，如但不限于脑淀粉样蛋白血管病或遗传性脑出血，与认知损害相关的疾病，如但不限于MCI（“轻度认知损害”），阿尔茨海默病，记忆丧失，与阿尔茨海默病相关的注意力缺陷症状，与疾病如阿尔茨海默病或痴呆症相关的神经退行性疾病，包括混合性血管性和退行性起源的痴呆，早老性痴呆，老年性痴呆和与帕金森病、进行性上核性麻痹或皮层基底节变性相关的痴呆。

  公开号：

  US20120165347A1
• 作为产物：
  描述：

  四氢-2 2-二甲基-4H-吡喃-4-酮 在 盐酸 、 sodium hexamethyldisilazane 作用下， 以 四氢呋喃 、 水 、 乙腈 为溶剂， 反应 6.5h， 生成 2,2-二甲基四氢吡喃-4-甲醛
  参考文献：
  名称：

  [EN] TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
  [FR] DÉRIVÉS DE TÉTRAHYDRONAPHTYRIDINE COMME MODULATEURS ALLOSTÉRIQUES NÉGATIFS DE MGLUR2, COMPOSITIONS ET LEUR UTILISATION

  摘要：

  提供的是化学式（I）中的喹啉羧酰胺和喹啉羧腈化合物，或其药用可接受的盐，其中R 1、R 2、L、X 1、X 2 和 X 3 如本文所定义。本发明的化合物及其药用可接受的盐，以及包含它们的药物组合物，可用作非竞争性mGluR2拮抗剂，或mGluR2负性变构调节剂（NAMs），并且可能在治疗需要的人群中发挥作用，用于引起疾病或疾病的方法中，其中mGluR2-NAM受体起因性作用，如阿尔茨海默病、认知障碍、精神分裂症和其他情绪障碍、疼痛障碍和睡眠障碍。

  公开号：

  WO2016029454A1

文献信息

• [EN] 4(SPIROPIPERIDINYL)METHYL SUBSTITUTED PYRROLIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY<br/>[FR] 4(SPIROPIPERIDINYL)METHYL PYRROLIDINES SUBSTITUEES SERVANT DE MODULATEURS DE L'ACTIVITE DES RECEPTEURS DES CHIMIOKINES
  申请人：MERCK & CO INC

  公开号：WO2004058763A1

  公开（公告）日：2004-07-15

  3-Substituted pyrrolidines having a spiropiperidinylmethyl substituent on the 4-position of the ring are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-3 and/or CCR-5.

  在环的4位上具有螺环哌啶甲基取代基的3-取代吡咯烷可用作化学因子受体活性调节剂。具体来说，这些化合物可用作化学因子受体CCR-3和/或CCR-5的调节剂。
• BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20130324529A1

  公开（公告）日：2013-12-05

  The present invention is related to novel benzimidazole compounds of formula (I) having cannabinoid receptor agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals, in particular humans.

  本发明涉及具有大麻素受体激动性质的新型苯并咪唑化合物（I）的公式，包括这些化合物的药物组合物，制备这些化合物的化学过程以及它们在治疗与大麻素受体在动物中介导相关的疾病，特别是人类中的用途。
• 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF
  申请人：Novartis AG

  公开号：US20200017461A1

  公开（公告）日：2020-01-16

  The present disclosure provides a compound of Formula (I′): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R x , X 1 , X 2 , and R 1 are as defined herein, and methods of making and using same.

  本公开提供了化合物Formula (I′)的一种： 或其药用可接受的盐、水合物、溶剂合物、前药、立体异构体或互变异构体，其中R x 、X 1 、X 2 和R 1 如本文所定义，并提供了制备和使用该化合物的方法。
• [EN] PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PYRROLO[2,3-B]PYRIDINE CDK9 KINASE
  申请人：ABBVIE INC

  公开号：WO2014139328A1

  公开（公告）日：2014-09-18

  Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).

  公开的是Formula (IIa)的化合物，其中R1、R2、R3A、R3B、R3C、R3D、R3E和R4如规范中所定义，并且其药用盐。这些化合物可用作治疗疾病，包括癌症的药物。还提供了包含一个或多个Formula (IIa)化合物的药物组合物。
• [EN] 3-(AMINOARYL)-PYRIDINE COMPOUNDS<br/>[FR] COMPOSÉS 3-(AMINOARYL)-PYRIDINE
  申请人：NOVARTIS AG

  公开号：WO2012066070A1

  公开（公告）日：2012-05-24

  The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided are pharmaceutical compositions containing these compounds and methods of treating a disease or condition mediated by CDK9 using these compounds and compositions.

  本发明提供了一种化合物，其化学式为（I）：以及药学上可接受的盐、对映体、立体异构体、转型异构体、互变异构体、二对映异构体或外消旋体。还提供了含有这些化合物的药物组合物，以及使用这些化合物和组合物治疗通过CDK9介导的疾病或症状的方法。